Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

The Dividend Kings underperformed in 2024. Read here to know about the top 18 most opportune Dividend Kings based on ...

BRG announced today that Rich Rieger has joined the firm's Health Analytics practice, where he will advise biopharmaceutical and MedTech companies on driving growth, performance improvement and ...